EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeitOpen Access · CC BY 4.0

Riboflavin treatment in L-2-hydroxyglutaric aciduria: report on a pediatric patient and literature review

Patryk Lipiński, Elżbieta Ciara, Anna Bogdańska, Elżbieta Jurkiewicz, Anna Tylki-Szymańska

Journal of Applied Genetics · 2025

DOI: 10.1007/s13353-025-00974-4 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Applied Genetics, 2025. Verfasst von Patryk Lipiński und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Sciences, Maria Skłodowska-Curie Medical Academy, Plac Żelaznej Bramy 10, 00-136, Warsaw, Poland. Patryk.lipinski.92@gmail.com. Hauptthemen laut MEDLINE: Riboflavin, Brain Diseases, Metabolic, Inborn, Alcohol Oxidoreductases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

L-2-hydroxyglutaric aciduria (L-2-HGA, #236,792) is an autosomal recessive neurodegenerative disorder caused by the deficiency of L-2-hydroxyglutarate dehydrogenase, a flavin adenine dinucleotide (FAD)-dependent enzyme, due to biallelic pathogenic variants in the L2HGDH gene. The present study described the patient with L2HGA presenting with a slight psychomotor delay, epilepsy from 5 years of age, non-progressive cerebellar ataxia, and mild to moderate intellectual disability during 10 years of follow-up. Two different heterozygous variants in the L2HGDH gene were identified in the patient: a known substitution c.829C > T(p.Arg277*) and a novel substitution c.1196 + 1G > A corresponding with significantly increased urinary L-2-hydroxyglutarate (L2HG) excretion. A 6-month period of treatment with riboflavin (100 mg/day) was implemented with no clinical nor biochemical effect.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RiboflavinBrain Diseases, Metabolic, InbornAlcohol OxidoreductasesHumansChild, PreschoolMaleGlutaratesFemaleIntellectual DisabilityChildMutationEpilepsy

Stichwörter der Autor:innen

Novel variant; L-2-hydroxyglutaric aciduria; L2HGDG gene; Riboflavin

Substanzen

RiboflavinAlcohol OxidoreductasesL2HGDH protein, humanGlutaratesalpha-hydroxyglutarate

Autor:innen und Institutionen

  • Institute of Clinical Sciences, Maria Skłodowska-Curie Medical Academy, Plac Żelaznej Bramy 10, 00-136, Warsaw, Poland. Patryk.lipinski.92@gmail.com.
  • Department of Medical Genetics, Children's Memorial Health Institute, Warsaw, Poland.
  • Department of Clinical Biochemistry, The Children's Memorial Health Institute, Warsaw, Poland.
  • Department of Diagnostic Imaging, The Children's Memorial Health Institute, Warsaw, Poland.
  • Department of Pediatric Nutrition and Metabolic Diseases, Children's Memorial Health Institute, Warsaw, Poland.

Zitieren

APA

Lipiński, P., Ciara, E., Bogdańska, A., Jurkiewicz, E., & Tylki-Szymańska, A. (2025). Riboflavin treatment in L-2-hydroxyglutaric aciduria: report on a pediatric patient and literature review. Journal of Applied Genetics. https://doi.org/10.1007/s13353-025-00974-4

Vancouver

Lipiński P, Ciara E, Bogdańska A, Jurkiewicz E, Tylki-Szymańska A. Riboflavin treatment in L-2-hydroxyglutaric aciduria: report on a pediatric patient and literature review. Journal of Applied Genetics. 2025. doi:10.1007/s13353-025-00974-4

BibTeX
@article{Lipiski2025,
  author = {Lipiński, Patryk and Ciara, Elżbieta and Bogdańska, Anna and Jurkiewicz, Elżbieta and Tylki-Szymańska, Anna},
  title = {Riboflavin treatment in L-2-hydroxyglutaric aciduria: report on a pediatric patient and literature review},
  journal = {Journal of Applied Genetics},
  year = {2025},
  doi = {10.1007/s13353-025-00974-4}
}
Kostenlos starten →